Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).The trial involved 51 patients aged 50 and older, randomized to receive either a medium or high dose of OCU410 or no treatment.Efficacy Signals Remain, But Below Interim TrendsThe optimal (mid-dose) cohort showed a 31% reduction in lesion growth versus control (p<0.05).Treatment slowed ellipsoid zone (EZ) loss by 27%, suggesting preservation of photoreceptor structure linked to visu ...